Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 26;8(2):e000764. doi: 10.1136/jitc-2020-000764

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

CCR4 blockade significantly reduces T_reg trafficking into tumors. (A) Messenger RNA expression of CCL17 (teal) and CCL22 (red) in different mouse tumors. (B) Representative flow cytometry plots showing percent of in vitro generated GFP⁺ T_reg and CCR4 expression prior to transfer into tumor-bearing animals. (C) In vivo T_reg migration in Pan02 tumor-bearing mice dosed with CCR4-351. Number of GFP⁺ T_reg in tumor (left) and spleen (right). (D) In vivo T_reg migration in the periphery. Number of GFP⁺ T_reg in blood and healthy skin tissue. For statistical analysis, the one-way analysis of variance (Kruskal-Wallis test; non-parametric or mixed) was used. n=8 mice (tumor), n=5 mice (spleen) and n=4 mice (skin and blood) were used in this study. Data is representative from two independent studies.